Is it safe?
Can TGTX take a bad year?
TG Therapeutics, Inc. carries $193M of net debt at 1.42× EBITDA: a load its earnings can carry.
$193M
Net debt · as at Q2 2026 · under two and a half years of EBITDA, comfortable
- Net debt / EBITDA
- 1.42×
Net debt / EBITDA · −0.08× a year ago · the load is going up
- Altman Z-score
- 11.94
Altman Z-score · safe zone, above 3
- Interest cover
- 3.64×
Interest cover · operating profit covers the interest bill, with room to spare
Details›
- Total debtQ2 2026
- $745M
- Cash and short-term investments
- $552M
- Net debt
- $193M
- EBITDA, trailing twelve months
- $136M
- Operating profit, trailing twelve months
- $136M
- Debt / equity
- 1.23×
- Total debt / EBITDA
- 5.46×
- Annualised volatilitytwo years of daily moves
- 56%
- Worst drawdown on file
- −93%
- Below its 52-week high
- −3.6%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.